Executive Series: Virtus Health (VRT) CEO, Sue Channon


In this short video we discuss VRTs’ full year results, which saw NPAT attributable to ordinary equity holders down 14.6% to $28.1m and included a final dividend 12 cents per share fully franked; VRT’s position in the domestic market where it remains the overall leader with 42.1% share of the Australian eastern states market; The importance of VRT’s diagnostic business where revenue increased by nearly 9% in FY17, delivering an EBITDA improvement over the prior year of 37% driven by the new applications of genetic testing and screening in reproductive medicine.


CommSec is Australia's leading online broker. CommSec has been committed to providing the best in online trading since 1995. CommSec helps make informed investment decisions with comprehensive market research, free live pricing and powerful...

ASX:VRT Virtus Health Fertility


Please sign in to comment on this wire.